Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0486 phase 1 dose-escalation and expansion study in B-cell non-Hodgkin lymphoma in Japan
jRCT2041230077Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of surovatamig in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), large-cell lymphoma and 1 more, sponsored by AstraZeneca. Primary endpoints: Objective response rate, Clinical benefit rate and 9 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
surovatamig
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)large-cell lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2041230077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041230077.